To investigate the possibility that Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) reduces the risk of cardiovascular events by suppressing inflammation in adipose tissue, this study examined the effects of SGLT2i on inflammatory factors (IL-6, iNOS, MCP-1) in THP-1 derived macrophages and 3T3-L1 derived white adipocyte cells to observe the effect of SGLT2i on inflammatory factors (IL-6, iNOS, and MCP-1). We also observed the effect of SGLT2i on the comprehensive metabolome of white adipocytes: in THP-1, dapagliflozin (Dapa) and empagliflozin (Empa) showed a tendency to decrease IL-6 mRNA. In white adipocytes, 30 μM Dapa significantly decreased IL-6 and iNOS mRNA and significantly increased methotionine (Met) and GABA. Metabolomic pathway analysis also showed significant variation in Glu-related metabolism. Furthermore, Met and GABA on white adipocytes tended to decrease IL-6 and MCP-1 in a concentration-dependent manner, similar to SGLT2i. These findings suggest that SGLT2i may act on both adipocytes and macrophages. Future studies are expected to elucidate the mechanism of action of SGLT2i via Met and GABA, which were found to correlate with the suppression of inflammation.